Boston Scientific (NYSE:BSX) Posts Earnings Results

Boston Scientific (NYSE:BSX) posted its quarterly earnings data on Wednesday. The medical equipment provider reported $0.73 EPS for the quarter, meeting analysts’ consensus estimates of $0.73, FiscalAI reports. The firm had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.09 billion. Boston Scientific had a net margin of 16.62% and a return on equity of 18.73%. The firm’s revenue was up 1.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.75 EPS.

Here are the key takeaways from Boston Scientific’s conference call:

• Q3 missed expectations: Organic revenue grew 1.5%, below the 3%–5% outlook, while adjusted EPS fell 3% to $0.73. The cybersecurity incident reduced revenue growth by roughly 300 basis points and EPS by approximately $0.07.
• Boston Scientific expects continued near-term pressure, guiding to a 1%–3% organic revenue decline and adjusted EPS of $0.77–$0.79 in Q4. Management said 2027 revenue and EPS growth will be challenging as EP and WATCHMAN face market-share and competitive pressures, while China pricing headwinds intensify.
• WATCHMAN sales declined 6% and EP sales declined 5% in Q3, with further EP share erosion expected until new products launch. The company also cited weaker urology performance, China-related pricing pressure, supply constraints, and delays affecting parts of its product pipeline.
• Management expects a return to stronger performance in 2028, supported by launches including FARAWAVE Ultra, 2D ICE, CRM’s Denali platform, new IVL and imaging technologies, and a potential Penumbra contribution. The company identified approximately $25 billion of new market opportunities by 2030.
• A company-wide restructuring program is expected to generate more than $500 million in savings over three years, with over half anticipated by the end of 2027. Boston Scientific said the program should improve operating leverage while preserving investment in key growth platforms.

Boston Scientific Stock Up 0.3%

Shares of BSX traded up $0.14 during trading hours on Friday, reaching $42.83. The company’s stock had a trading volume of 3,633,534 shares, compared to its average volume of 18,660,314. The company has a 50 day moving average of $44.93 and a two-hundred day moving average of $57.15. Boston Scientific has a 1-year low of $39.57 and a 1-year high of $105.65. The firm has a market cap of $62.08 billion, a price-to-earnings ratio of 18.15, a P/E/G ratio of 1.04 and a beta of 0.58. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Despite reducing forecasts, several analysts still see upside. UBS maintained a Buy rating with a $57 target, while Needham and BTIG also retained Buy ratings; Bernstein, Baird and UBS targets remain above the current share price. Analyst upgrades and downgrades
• Positive Sentiment: Management continues to express confidence in Boston Scientific’s long-term strategy, while reported revenue of approximately $5.14 billion exceeded consensus expectations. The company also said it is targeting renewed growth after the expected 2027 trough. Boston Scientific long-term investor takeaways
• Neutral Sentiment: Third-quarter adjusted EPS of $0.73 met estimates and revenue increased year over year, but the results were overshadowed by lower margins, soft segment performance and reduced full-year guidance. BSX third-quarter earnings
• Negative Sentiment: An eight-day cybersecurity outage reduced third-quarter sales by roughly $150 million and continues to disrupt operations. Management’s fourth-quarter outlook implies declining sales and adjusted EPS of $0.77–$0.79, below market expectations. Boston Scientific cybersecurity impact
• Negative Sentiment: Analyst sentiment has deteriorated: TD Cowen downgraded BSX to Hold with a $46 target, JPMorgan moved to Neutral, and Oppenheimer cut its rating to Market Perform. Zacks also added the shares to its Strong Sell list. TD Cowen rating
• Negative Sentiment: Investors are also concerned about electrophysiology and WATCHMAN weakness, China pricing pressure and expectations for largely flat growth in 2027, all of which could delay the company’s earnings recovery. BSX growth challenges through 2027

Analysts Set New Price Targets

BSX has been the topic of a number of recent research reports. Argus downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Friday, July 31st. Wall Street Zen cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Sunday, August 2nd. Raymond James Financial reiterated an “outperform” rating and set a $57.00 price objective (down from $78.00) on shares of Boston Scientific in a research report on Thursday, July 30th. Needham & Company LLC lowered their price target on Boston Scientific from $57.00 to $48.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Robert W. Baird raised their price target on Boston Scientific from $50.00 to $51.00 and gave the company an “outperform” rating in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $61.43.

Insiders Place Their Bets

In other news, CEO Michael Mahoney acquired 186,240 shares of Boston Scientific stock in a transaction that occurred on Monday, August 3rd. The stock was purchased at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the transaction, the chief executive officer owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director David Habiger purchased 2,100 shares of the business’s stock in a transaction dated Wednesday, August 5th. The shares were purchased at an average cost of $47.59 per share, with a total value of $99,939.00. Following the completion of the purchase, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. This represents a 13.94% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 189,522 shares of company stock worth $9,157,810 over the last ninety days. 0.34% of the stock is currently owned by company insiders.

Boston Scientific Company Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.